FORMULATION AND EVALUATION OF BILAYER TABLET OF DAPAGLIFLOZIN AND VILDAGLIPTIN

Abstract

Diabetes is a chronic illness that results from insufficient insulin production by the pancreas or from inefficient insulin usage by the body. Combination therapy employing two antidiabetic medications effectively manages these numerous problems. The creation of the bi-layer tablet, which combines several qualities with a controlled release formulation, is a new chapter in the successful delivery of medication. The goal of the current study was to create bi-layer tablets containing Dapagliflozin fast dissolving and Vildagliptin gastro retentive tablets. At first, about nine formulations of Dapagliflozin instant release tablets were prepared Result of pre compression parameter for these nine formulations were found to be within limits. The result of post compression parameter revealed that maximum drug content in formulation IF7 which is 99.45±0.26. Further about eight formulations of Vildagliptin tablets were prepared. The post compression properties of Vildagliptin tablets revealed that maximum drug content of 99.45±0.14 in F7 formulation. The post compression parameter of bilayer tablet was then performed. The hardness & friability was estimated to be 6.8 kg/cm² & 0.658 % respectively while the thickness was found to be 5.12mm.  The drug content in bilayer tablet was observed to be 99.18% for Dapagliflozin and 99.45% for Vildagliptin. According to dissolution rate studies of bilayer tablets it was observed that within 1.5 hour the % drug release with respect to Dapagliflozin was 98.65% while for Vildagliptin it was 98.14% in 12 hours. The current investigation found that bilayer tablets containing Dapagliflozin and Vildagliptin may be a preferable option than standard dosage forms